Screener
TG Therapeutics TGTX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|
| Proceeds from debt financings, net of debt discount costs | 747,656 | — |
| Financing costs paid | (2,598) | — |
| Purchase of treasury stock | (99,992) | (12,998) |
| Net cash provided by (used in) financing activities | 390,914 | (12,545) |
| NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 403,449 | (50,750) |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF PERIOD | 80,490 | 181,192 |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD | $483,939 | $130,442 |
| Reconciliation to amounts on condensed consolidated balance sheets: |
Document
FAQ
- What is TG Therapeutics's financing cash flow?
- TG Therapeutics (TGTX) reported financing cash flow of $85K in Q2 2026.
- How has TG Therapeutics's financing cash flow changed year-over-year?
- TG Therapeutics's financing cash flow increased by 101.3% year-over-year, from -$6.44M to $85K.
- What is the long-term trend for TG Therapeutics's financing cash flow?
- Over 3 years (2021 to 2025), TG Therapeutics's financing cash flow has grown at a 29.9% compound annual growth rate (CAGR), from $41.42M to -$90.79M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about TG Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude